KUSTE BIOPHARMA

KUSTE BIOPHARMA is a biopharmaceutical Clinical Stage company recently founded by seasoned Life Sciences entrepreneurs, inheriting anti-inflammatory compounds locally released, that have achieved results in Phase 3 for eye and ears diseases. KUSTE BIOPHARMA is expanding the use of these molecules to inflammatory Uro-Gastro diseases whose medical needs are currently unmet, such as Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS). Existing data support also other possible developments, like Inflammatory Bowel Disease (IBD). KUSTE BIOPHARMA has closed a relevant financial round entering Phase 2 clinical studies on IC/PBS.